{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T03:42:58Z","timestamp":1794454978845,"version":"4.9.1"},"reference-count":57,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,18]],"date-time":"2021-10-18T00:00:00Z","timestamp":1634515200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008732","name":"Uehara Memorial Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008732","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003083","name":"European Association of Urology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003083","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.euo.2021.10.003","type":"journal-article","created":{"date-parts":[[2021,11,6]],"date-time":"2021-11-06T17:13:31Z","timestamp":1636218811000},"page":"927-942","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":119,"title":["Diagnostic Accuracy of Novel Urinary Biomarker Tests in Non\u2013muscle-invasive Bladder Cancer: A Systematic Review and Network Meta-analysis"],"prefix":"10.1016","volume":"4","author":[{"given":"Ekaterina","family":"Laukhtina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Ryul","family":"Shim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichiro","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"D\u2018Andrea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Soria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawel","family":"Rajwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadi","family":"Mostafaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Comp\u00e9rat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Cimadamore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Moschini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy Yuen-Chun","family":"Teoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dmitry","family":"Enikeev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evanguelos","family":"Xylinas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yair","family":"Lotan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Palou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Gontero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marko","family":"Babjuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Alfred","family":"Witjes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish M.","family":"Kamat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan","family":"Roupret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahrokh F.","family":"Shariat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7768-8558","authenticated-orcid":false,"given":"Benjamin","family":"Pradere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2021.10.003_b0005","series-title":"EAU Guidel. Edn. Present. EAU Annu. Congr. Milan 2021","article-title":"EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer","author":"Witjes","year":"2021"},{"key":"10.1016\/j.euo.2021.10.003_b0010","doi-asserted-by":"crossref","DOI":"10.1111\/j.1464-410X.2006.06036.x","article-title":"Institutional variability in the accuracy of urinary cytology for predicting recurrence of transitional cell carcinoma of the bladder","author":"Karakiewicz","year":"2006","journal-title":"BJU Int"},{"key":"10.1016\/j.euo.2021.10.003_b0015","doi-asserted-by":"crossref","first-page":"693","DOI":"10.2147\/CEOR.S274951","article-title":"Humanistic and Economic Burden of Non-Muscle Invasive Bladder Cancer\u202f: Results of Two Systematic Literature Reviews","author":"Lee","year":"2020","journal-title":"Clin Outcomes Res"},{"key":"10.1016\/j.euo.2021.10.003_b0020","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1007\/s00345-018-2380-x","article-title":"An up-to-date catalog of available urinary biomarkers for the surveillance of non-muscle invasive bladder cancer","volume":"36","author":"Soria","year":"2018","journal-title":"World J Urol"},{"key":"10.1016\/j.euo.2021.10.003_b0025","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.juro.2016.06.049","article-title":"Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA\/SUO Guideline","volume":"196","author":"Chang","year":"2016","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2021.10.003_b0030","first-page":"161","article-title":"Novel urinary biomarkers ADXBLADDER and bladder EpiCheck for diagnostics of bladder cancer: A review","volume":"39","author":"Wolfs","year":"2021","journal-title":"Urol Oncol Semin Orig Investig"},{"key":"10.1016\/j.euo.2021.10.003_b0035","article-title":"Diagnostic test accuracy: application and practice using R software","author":"Shim","year":"2019","journal-title":"Epidemiol Health"},{"key":"10.1016\/j.euo.2021.10.003_b0040","doi-asserted-by":"crossref","first-page":"889","DOI":"10.7326\/0003-4819-149-12-200812160-00008","article-title":"Systematic reviews of diagnostic test accuracy","volume":"149","author":"Leeflang","year":"2008","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.euo.2021.10.003_b0045","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1001\/jama.2017.19163","article-title":"Preferred Reporting Items for a Systematic Review and Meta-analysis of Diagnostic Test Accuracy Studies: The PRISMA-DTA Statement","volume":"319","author":"McInnes","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.euo.2021.10.003_b0050","doi-asserted-by":"crossref","DOI":"10.7326\/0003-4819-155-8-201110180-00009","article-title":"Quadas-2: A revised tool for the quality assessment of diagnostic accuracy studies","author":"Whiting","year":"2011","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.euo.2021.10.003_b0055","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.jclinepi.2005.02.022","article-title":"Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews","volume":"58","author":"Reitsma","year":"2005","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.euo.2021.10.003_b0060","article-title":"Network meta-analysis: application and practice using the R software","volume":"41","author":"Shim","year":"2019","journal-title":"Epidemiol Health"},{"key":"10.1016\/j.euo.2021.10.003_b0065","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1111\/1467-9868.00353","article-title":"Bayesian measures of model complexity and fit","volume":"64","author":"Spiegelhalter","year":"2002","journal-title":"J R Stat Soc Ser B Stat Methodol"},{"key":"10.1016\/j.euo.2021.10.003_b0070","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1002\/sim.1875","article-title":"Combination of direct and indirect evidence in mixed treatment comparisons","volume":"23","author":"Lu","year":"2004","journal-title":"Stat Med"},{"key":"10.1016\/j.euo.2021.10.003_b0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.jclinepi.2010.03.016","article-title":"Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: An overview and tutorial","author":"Salanti","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.euo.2021.10.003_b0080","doi-asserted-by":"crossref","DOI":"10.1186\/s12874-015-0060-8","article-title":"Ranking treatments in frequentist network meta-analysis works without resampling methods","author":"R\u00fccker","year":"2015","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.euo.2021.10.003_b0085","doi-asserted-by":"crossref","DOI":"10.1007\/s00345-021-03629-1","article-title":"Assessment of Xpert Bladder Cancer Monitor test performance for the detection of recurrence during non-muscle invasive bladder cancer follow-up","author":"Cancel-Tassin","year":"2021","journal-title":"World J Urol"},{"key":"10.1016\/j.euo.2021.10.003_b0090","doi-asserted-by":"crossref","DOI":"10.1111\/bju.15418","article-title":"Longitudinal Follow-up and Performance Validation of a mRNA-based Urine Test (Xpert\u00ae Bladder Cancer Monitor) for surveillance in Non-Muscle Invasive Bladder Cancer Patients","author":"Cowan","year":"2021","journal-title":"BJU Int"},{"key":"10.1016\/j.euo.2021.10.003_b0095","doi-asserted-by":"crossref","first-page":"77.e9","DOI":"10.1016\/j.urolonc.2020.07.013","article-title":"Prospective Validation of Clinical Usefulness of a Novel mRNA-based Urine Test (Xpert\u00ae Bladder Cancer Monitor) for surveillance in Non Muscle Invasive Bladder Cancer","volume":"39","author":"Elsawy","year":"2021","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euo.2021.10.003_b0100","article-title":"Can repeat biopsy be skipped after initial complete resection of T1 bladder cancer? The role of a novel urinary mRNA biomarker","author":"Elsawy","year":"2021","journal-title":"Urol Oncol Semin Orig Investig"},{"key":"10.1016\/j.euo.2021.10.003_b0105","first-page":"1","article-title":"Diagnostic value of Xpert \u00ae Bladder Cancer Monitor in the follow-up of patients affected by non-muscle invasive bladder cancer : an update","author":"D\u2019Elia","year":"2021","journal-title":"Ther Adv Urol"},{"key":"10.1016\/j.euo.2021.10.003_b0110","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1007\/s00345-019-03002-3","article-title":"Clinical performance of Xpert Bladder Cancer (BC) Monitor, a mRNA - based urine test, in active surveillance (AS) patients with recurrent non - muscle - invasive bladder cancer (NMIBC): results from the Bladder Cancer Italian Active Surveillance","volume":"38","author":"Hurle","year":"2020","journal-title":"World J Urol"},{"key":"10.1016\/j.euo.2021.10.003_b0115","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/bju.14019","article-title":"Increased accuracy of a novel mRNA-based urine test for bladder cancer surveillance","volume":"121","author":"Pichler","year":"2018","journal-title":"BJU Int"},{"key":"10.1016\/j.euo.2021.10.003_b0120","article-title":"The performance of the Xpert Bladder Cancer Monitor Test and voided urinary cytology in the follow-up of urinary bladder tumors","author":"Smrkolj","year":"2021","journal-title":"Radiol Oncol"},{"key":"10.1016\/j.euo.2021.10.003_b0125","first-page":"853","article-title":"Prospective Validation of an mRNA-based Urine Test for Surveillance of Patients with Bladder Cancer","volume":"75","author":"Van","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2021.10.003_b0130","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/cncy.22246","article-title":"Comparison of 2 New Real-Time Polymerase Chain Reaction \u2013 Based Urinary Markers in the Follow-Up of Patients With Non \u2013 Muscle-Invasive Bladder Cancer","author":"Trenti","year":"2020","journal-title":"Cancer Cytopathol"},{"key":"10.1016\/j.euo.2021.10.003_b0135","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1111\/bju.14673","article-title":"Diagnostic accuracy, clinical utility and influence on decision-making of a methylation urine biomarker test in the surveillance of non-muscle-invasive bladder cancer","volume":"123","author":"D\u2019Andrea","year":"2019","journal-title":"BJU Int"},{"key":"10.1016\/j.euo.2021.10.003_b0140","first-page":"131.e17","article-title":"The combination cytology\/epichek test in non muscle invasive bladder carcinoma follow-up: Effective tool or useless expence?","volume":"39","author":"Pierconti","year":"2021","journal-title":"Urol Oncol Semin Orig Investig"},{"key":"10.1016\/j.euo.2021.10.003_b0145","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/cncy.22152","article-title":"Diagnostic predictive value of the Bladder EpiCheck test in the follow-up of patients with non\u2013muscle-invasive bladder cancer","volume":"127","author":"Trenti","year":"2019","journal-title":"Cancer Cytopathol"},{"key":"10.1016\/j.euo.2021.10.003_b0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.juro.2016.02.2496","article-title":"Mp13-15 Molecular Urine Cytology \u2013 Bladder Epicheck Is a Novel Molecular Diagnostic Tool for Monitoring of Bladder Cancer Patients","volume":"195","author":"Wasserstrom","year":"2016","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2021.10.003_b0155","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1097\/JU.0000000000001084","article-title":"Diagnostic Accuracy of MCM5 for the Detection of Recurrence in Nonmuscle Invasive Bladder Cancer Followup: A Blinded, Prospective Cohort, Multicenter European Study","volume":"204","author":"Roupret","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2021.10.003_b0160","doi-asserted-by":"crossref","first-page":"139","DOI":"10.3233\/CBM-200316","article-title":"MCM5 urine expression (ADXBLADDER) is a reliable biomarker of high-risk non- muscle-invasive bladder cancer recurrence: A prospective matched case-control study","volume":"30","author":"Bia\u0142ek","year":"2021","journal-title":"Cancer Biomarkers"},{"key":"10.1016\/j.euo.2021.10.003_b0165","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1111\/bju.15194","article-title":"Comparison of the performances of the ADXBLADDER test and urinary cytology in the follow-up of non-muscle-invasive bladder cancer: a blinded prospective multicentric study","volume":"127","author":"Gontero","year":"2021","journal-title":"BJU Int"},{"key":"10.1016\/j.euo.2021.10.003_b0170","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fgene.2019.01237","article-title":"Validation of a Novel, Sensitive, and Specific Urine-Based Test for Recurrence Surveillance of Patients With Non-Muscle-Invasive Bladder Cancer in a Comprehensive Multicenter Study","volume":"10","author":"Batista","year":"2019","journal-title":"Front Genet"},{"key":"10.1016\/j.euo.2021.10.003_b0175","doi-asserted-by":"crossref","DOI":"10.3390\/diagnostics10100745","article-title":"Clinical validation of a urine test (uromonitor-V2\u00ae) for the surveillance of non-muscle-invasive bladder cancer patients","volume":"10","author":"Sieverink","year":"2020","journal-title":"Diagnostics"},{"key":"10.1016\/j.euo.2021.10.003_b0180","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12894-020-0583-0","article-title":"An evaluation of the real world use and clinical utility of the Cxbladder Monitor assay in the follow-up of patients previously treated for bladder cancer","volume":"20","author":"Koya","year":"2020","journal-title":"BMC Urol"},{"key":"10.1016\/j.euo.2021.10.003_b0185","first-page":"531.e15","article-title":"Clinical comparison of noninvasive urine tests for ruling out recurrent urothelial carcinoma","volume":"35","author":"Lotan","year":"2017","journal-title":"Urol Oncol Semin Orig Investig"},{"key":"10.1016\/j.euo.2021.10.003_b0190","doi-asserted-by":"crossref","first-page":"05","DOI":"10.1097\/JU.0000000000000593","article-title":"Use and Validation of the AUA\/SUO Risk Grouping for Nonmuscle Invasive Bladder Cancer in a Contemporary Cohort","volume":"203","author":"Ritch","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2021.10.003_b0195","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.euo.2020.09.001","article-title":"Validation of an mRNA-based Urine Test for the Detection of Bladder Cancer in Patients with Haematuria","volume":"4","author":"Van Valenberg","year":"2020","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2021.10.003_b0200","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.juro.2017.09.141","article-title":"Development of a 90-Minute Integrated Noninvasive Urinary Assay for Bladder Cancer Detection","volume":"199","author":"Wallace","year":"2018","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2021.10.003_b0205","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1002\/dc.24530","article-title":"Predictive value of MCM5 (ADXBLADDER) analysis in urine of men evaluated for the initial diagnosis of bladder cancer: A comparative prospective study","volume":"48","author":"Anastasi","year":"2020","journal-title":"Diagn Cytopathol"},{"key":"10.1016\/j.euo.2021.10.003_b0210","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.euo.2019.06.006","article-title":"A Novel, non-invasive Test Enabling Bladder Cancer Detection in Urine Sediment of Patients Presenting with Haematuria\u2014A Prospective Multicentre Performance Evaluation of ADXBLADDER","volume":"3","author":"Dudderidge","year":"2019","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2021.10.003_b0215","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.juro.2012.05.003","article-title":"A multigene urine test for the detection and stratification of bladder cancer in patients presenting with hematuria","volume":"188","author":"O\u2019Sullivan","year":"2012","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2021.10.003_b0220","first-page":"55","article-title":"Inclusion of a molecular marker of bladder cancer in a clinical pathway for investigation of haematuria may reduce the need for cystoscopy","volume":"132","author":"Davidson","year":"2019","journal-title":"N Z Med J"},{"key":"10.1016\/j.euo.2021.10.003_b0225","first-page":"7965","article-title":"Nuclear matrix protein 22 (NMP22) test in the diagnosis of bladder cancer: A meta-analysis","volume":"9","author":"Fu","year":"2016","journal-title":"Int J Clin Exp Med"},{"key":"10.1016\/j.euo.2021.10.003_b0230","doi-asserted-by":"crossref","unstructured":"hou R, Gore JL, Buckley D, Fu R, Gustafson K, Griffin JC, et al. A Systematic Review and Meta-analysis Annals of Internal Medicine Urinary Biomarkers for Diagnosis of Bladder Cancer 2015. https:\/\/doi.org\/10.7326\/M15-0997.","DOI":"10.7326\/M15-0997"},{"key":"10.1016\/j.euo.2021.10.003_b0235","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.eururo.2015.10.024","article-title":"Economic Burden of Bladder Cancer Across the European Union","volume":"69","author":"Leal","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2021.10.003_b0240","first-page":"1","article-title":"Alternating Cystoscopy with Bladder EpiCheck \u00ae in the Surveillance of Low-Grade Intermediate-Risk NMIBC: A Cost Comparison Model","author":"Lotan","year":"2021","journal-title":"Bl Cancer"},{"key":"10.1016\/j.euo.2021.10.003_b0245","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.urology.2019.04.036","article-title":"Overuse of Cystoscopic Surveillance Among Patients With Low-risk Non-Muscle-invasive Bladder Cancer - A National Study of Patient, Provider, and Facility Factors","author":"Han","year":"2019","journal-title":"Urology"},{"key":"10.1016\/j.euo.2021.10.003_b0250","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1097\/MOU.0000000000000550","article-title":"The conundrum of recurrent low-grade tumours: To treat or to observe?","volume":"28","author":"Brummelhuis","year":"2018","journal-title":"Curr Opin Urol"},{"key":"10.1016\/j.euo.2021.10.003_b0255","doi-asserted-by":"crossref","DOI":"10.1016\/j.euo.2021.05.002","article-title":"Long-term Follow-up and Factors Associated with Active Surveillance Failure for Patients with Non-muscle-invasive Bladder Cancer: The Bladder Cancer Italian Active Surveillance (BIAS) Experience","author":"Contieri","year":"2021","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2021.10.003_b0260","first-page":"886","article-title":"Toward noninvasive follow-up of low-risk bladder cancer \u2013 Rationale and concept of the UroFollow trial*","volume":"38","author":"Benderska-S\u00f6der","year":"2020","journal-title":"Urol Oncol Semin Orig Investig"},{"key":"10.1016\/j.euo.2021.10.003_b0265","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.eururo.2019.04.035","article-title":"Evaluation of Cxbladder and Adjudication of Atypical Cytology and Equivocal Cystoscopy(Figure presented.)","volume":"76","author":"Konety","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2021.10.003_b0270","doi-asserted-by":"crossref","DOI":"10.1016\/j.eururo.2007.09.036","article-title":"Challenges of Cancer Biomarker Profiling","author":"Bensalah","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2021.10.003_b0275","article-title":"Urinary-based tumor markers enhance microhematuria risk stratification according to baseline bladder cancer prevalence","author":"Woldu","year":"2021","journal-title":"Urol Oncol Semin Orig Investig"},{"key":"10.1016\/j.euo.2021.10.003_b0280","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S1470-2045(21)00004-8","article-title":"Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial","volume":"22","author":"Bellmunt","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euo.2021.10.003_b0285","doi-asserted-by":"crossref","DOI":"10.1111\/bju.15483","article-title":"The IDENTIFY Study: The Investigation and Detection of Urological Neoplasia in Patients Referred with Suspected Urinary Tract Cancer; A multicentre observational study","author":"Khadhouri","year":"2021","journal-title":"BJU Int"}],"updated-by":[{"DOI":"10.1016\/j.euo.2022.01.003","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000}}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931121001838?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931121001838?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,12,16]],"date-time":"2021-12-16T02:45:07Z","timestamp":1639622707000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931121001838"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":57,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S2588931121001838"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2021.10.003","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Diagnostic Accuracy of Novel Urinary Biomarker Tests in Non\u2013muscle-invasive Bladder Cancer: A Systematic Review and Network Meta-analysis","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2021.10.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}